Editas Medicine (EDIT) Total Non-Current Liabilities (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Total Non-Current Liabilities of $156.4 million for Q4 2025, down 23.41% year-over-year from $204.2 million in Q4 2024, and down 14.8% quarter-over-quarter from $183.6 million in Q3 2025.
Editas Medicine (EDIT) Total Non-Current Liabilities (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Total Non-Current Liabilities for 10 consecutive years, with $156.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 23.41% year-over-year to $156.4 million; the TTM figure through Dec 2025 stood at $156.4 million (down 23.41% YoY), while the FY2025 annual figure was $156.4 million, down 23.41% from the prior year.
- Total Non-Current Liabilities eased to $156.4 million in Q4 2025 per EDIT's latest filing, from $183.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $204.2 million in Q4 2024 and bottomed at $142.5 million in Q1 2024.
- Historically, Total Non-Current Liabilities has averaged $166.8 million across 4 years, with a median of $155.0 million in 2022.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 37.76% — and 2025, when it declined 23.41%.
- Editas Medicine's Total Non-Current Liabilities stood at $153.6 million in 2022, then retreated by 3.5% to $148.3 million in 2023, then soared by 37.76% to $204.2 million in 2024, then dropped by 23.41% to $156.4 million in 2025.
- Business Quant data shows EDIT's Total Non-Current Liabilities at $156.4 million in Q4 2025, $183.6 million in Q3 2025, and $186.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 156.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 156.43 Mn |
| Sep 30, 2025 | 183.61 Mn |
| Jun 30, 2025 | 186.80 Mn |
| Mar 31, 2025 | 194.87 Mn |
| Dec 31, 2024 | 204.24 Mn |
| Sep 30, 2024 | 148.65 Mn |
| Jun 30, 2024 | 149.02 Mn |
| Mar 31, 2024 | 142.47 Mn |
| Dec 31, 2023 | 148.26 Mn |
| Dec 31, 2022 | 153.64 Mn |
| Dec 31, 2020 | 151.52 Mn |
| Mar 31, 2020 | 232.17 Mn |
| Dec 31, 2019 | 246.45 Mn |
| Sep 30, 2019 | 162.37 Mn |
| Jun 30, 2019 | 162.56 Mn |
| Mar 31, 2019 | 161.75 Mn |
| Dec 31, 2018 | 183.93 Mn |
| Sep 30, 2018 | 162.88 Mn |
| Jun 30, 2018 | 161.89 Mn |
| Mar 31, 2018 | 156.16 Mn |